Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MEGF8 controls osteogenic differentiation through post-transcriptional regulation of BMP-SMAD signaling in craniosynostosis.

Cell death and differentiation·2026
Same author

Species-specific regulation of necroptosis by STK38-dependent RIPK1 phosphorylation.

Cell death and differentiation·2026
Same author

Visualizing Millisecond Atomic Dynamics of Nanocrystals in Liquid.

Journal of the American Chemical Society·2026
Same author

Implicit Neural Representation with Dead-Free Linear Unit for Remote Sensing Images.

Sensors (Basel, Switzerland)·2026
Same author

The Korean Medicine HOme Medical care for the Elderly (K-HOME) registry: A study protocol for a multicenter registry on aging in place and functional recovery.

PloS one·2026
Same author

Two-dimensional hard masks push three-dimensional patterning.

Nature materials·2026

Related Experiment Video

Updated: Jun 21, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.7K

Development of a targeted IL-12 immunotherapy platform for B-cell lymphomas.

Dahea Lee1, Dongsu Kim2, Donggeon Kim2

  • 1Kanaph Therapeutics, Seoul, South Korea; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea.

International Immunopharmacology
|July 13, 2024
PubMed
Summary

A novel immunotherapy approach using a modified Interleukin-12 (IL-12) molecule, CD20-IL-12mut, effectively targets and eliminates B-cell lymphoma. This targeted therapy shows potent anticancer activity and generates lasting immune memory, offering a promising new treatment option.

Keywords:
Bispecific antibodyDrug developmentIL-12 mutationNHLRituximabTargeted delivery

More Related Videos

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

5.6K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

708

Related Experiment Videos

Last Updated: Jun 21, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.7K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

5.6K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

708

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Immunotherapy harnesses the immune system for cancer treatment, but enhancing effectiveness and safety remains a challenge.
  • Interleukin-12 (IL-12) shows promise for cancer therapy, yet systemic administration led to inefficacy and adverse effects.
  • Targeted delivery strategies are crucial for optimizing IL-12-based cancer treatments.

Purpose of the Study:

  • To develop an innovative IL-12-based therapeutic platform for enhanced cancer treatment.
  • To create a targeted IL-12 mutant molecule (IL-12mut) linked to a tumor-targeting arm.
  • To evaluate the efficacy of the CD20-IL-12mut construct in a B-cell lymphoma model.

Main Methods:

  • Development of a single-chain IL-12 mutant (IL-12mut) conjugated to a tumor-targeting moiety.
  • Creation of the TMEkine™ platform utilizing the CD20-IL-12mut construct.
  • In vivo assessment of CD20-IL-12mut efficacy in a B-cell lymphoma model.

Main Results:

  • CD20-IL-12mut demonstrated potent anticancer activity, inducing complete tumor regression.
  • The targeted approach minimized off-target effects associated with systemic IL-12 administration.
  • Treatment with CD20-IL-12mut generated robust immunological memory against tumor antigens.

Conclusions:

  • The CD20-IL-12mut molecule represents a highly effective IL-12-based therapeutic platform.
  • Targeted delivery of attenuated IL-12 mutants offers a promising strategy for cancer therapy.
  • CD20-IL-12mut warrants further investigation as a potential treatment for B-cell lymphomas, including non-Hodgkin's lymphoma.